The clinical data presented in this study demonstrated that CD19-22.BB.z-CAR T cells were clinically active in both B-ALL, with 82% achieving an MRD− CR, and in LBCL with an ORR of 62%. Here, CD19 is linked to acute lymphoblastic leukemia.